CSF markers related to pathogenetic mechanisms in Alzheimer's disease.

Autor: Mulder, C., Schoonenboom, S. N. M., Wahlund, L.-O., Scheltens, Ph., van Kamp, G. J., Veerhuis, R., Hack, C. E., Blomberg, M., Schutgens, R. B. H., Eikelenboom, P.
Předmět:
Zdroj: Journal of Neural Transmission; Dec2002, Vol. 109 Issue 12, p1491-1498, 8p
Abstrakt: Summary. Serum amyloid P component (SAP) and complement C1q are found highly co-localized with extracellular fibrillar amyloidβ (Aβ) deposits in Alzheimer's disease (AD) brain. Conflicting data were reported earlier about the cerebrospinal fluid (CSF) levels of SAP and C1q in AD compared to controls. The objective of the present study was to compare the levels of Aβ1–42, tau, C1q and SAP in CSF of a well characterized group of AD patients and controls, and to assess the association with dementia severity. Significantly decreased CSF levels of Aβ1–42 were observed in the AD group (480 ± 104 ng/L) as compared to controls (1,040 ± 213 ng/L), whereas tau levels were significantly higher in patients with AD (618 ± 292 ng/L) than in controls (277 ± 136 ng/L). Combining the results of Aβ1–42 and tau measurements resulted in a clear separation between the AD group and the controls. No significant differences in CSF levels of SAP and C1q were observed between the well characterized AD patients and non demented control group. Furthermore, we could not demonstrate a correlation between SAP and C1q CSF levels and the severity of the disease, expressed in Mini-Mental State Examination (MMSE) scores. Therefore, in our opinion these factors can be excluded from the list of potentially interesting biomarkers for AD diagnosis and progression. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: